FDA drug class
Gadolinium-based Contrast Agents list
Every FDA-approved prescription drug the FDA NDC directory tags with the Gadolinium-based Contrast Agent [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 4 single-ingredient drugs in this class: gadobenate dimeglumine, gadobutrol, gadoterate, gadoxetate.
Run it in Rivvi
Map MultiHance and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Gadolinium-based Contrast Agents (4)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Gadobenate dimeglumine | MultiHance | Single ingredient | 2 | Not controlled |
| Gadobutrol | Gadavist | Single ingredient | 21 | Not controlled |
| Gadoterate | Dotarem | Single ingredient | 14 | Not controlled |
| Gadoxetate | Eovist | Single ingredient | 1 | Not controlled |
FDA established pharmacologic class: Gadolinium-based Contrast Agent [EPC].
Questions
What drugs are Gadolinium-based Contrast Agents?
The FDA NDC directory lists 4 single-ingredient drugs in this class: gadobenate dimeglumine, gadobutrol, gadoterate, gadoxetate.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.